The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! The stock decreased 4.37% or $0.2 during the last trading session, hitting $4.38. About 3.57 million shares traded hands or 63.01% up from the average. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 56.31% since April 6, 2016 and is uptrending. It has outperformed by 54.36% the S&P500.
The move comes after 7 months negative chart setup for the $823.75M company. It was reported on Nov, 8 by Barchart.com. We have $4.03 PT which if reached, will make NASDAQ:SGYP worth $65.90M less.
Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on November, 14. They expect $-0.22 EPS, up 4.35% or $0.01 from last year’s $-0.23 per share. After $-0.23 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -4.35% EPS growth.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Ratings Coverage
Out of 5 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Synergy Pharmaceuticals has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. On Tuesday, August 25 the stock rating was initiated by BTIG Research with “Buy”. On Friday, December 18 the stock rating was downgraded by Citigroup to “Neutral”. The rating was reinitiated by TH Capital with “Buy” on Thursday, October 29. The stock has “” rating given by Roth Capital on Thursday, October 29. The firm has “Buy” rating by Rodman & Renshaw given on Monday, May 9. The stock has “Neutral” rating given by Citigroup on Wednesday, March 16. The firm has “Buy” rating given on Monday, March 21 by Rodman & Renshaw. H.C. Wainwright initiated the shares of SGYP in a report on Thursday, October 1 with “Buy” rating.
According to Zacks Investment Research, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.”
Insitutional Activity: The institutional sentiment increased to 1.61 in 2016 Q2. Its up 0.55, from 1.06 in 2016Q1. The ratio is positive, as 16 funds sold all Synergy Pharmaceuticals Inc shares owned while 28 reduced positions. 25 funds bought stakes while 46 increased positions. They now own 99.69 million shares or 58.37% more from 62.94 million shares in 2016Q1.
Moreover, Thompson Siegel & Walmsley has 0.01% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 163,334 shares. National Bank & Trust Of Montreal Can owns 33,103 shares or 0% of their US portfolio. Sequoia Advisors Ltd Liability Corp, a Ohio-based fund reported 16,210 shares. Strategic Inv Management Ltd Llc accumulated 0.06% or 30,381 shares. Comml Bank Of America De has invested 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Integral Derivatives Lc last reported 10,800 shares in the company. Price T Rowe Assoc Md holds 88,600 shares or 0% of its portfolio. Landscape Capital Mngmt Limited Company holds 0.24% or 474,788 shares in its portfolio. Moreover, Carl Domino Inc has 0.32% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 89,000 shares. Tiaa Cref Inv Lc, a New York-based fund reported 1.05M shares. Geode Cap Ltd Liability accumulated 1.28 million shares or 0% of the stock. The California-based Dafna Cap Mngmt Limited Co has invested 0.96% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Blackrock Inv Management Limited Liability accumulated 704,495 shares or 0% of the stock. Ameriprise Financial holds 0% or 17,390 shares in its portfolio. Tocqueville Asset Management L P reported 55,000 shares or 0% of all its holdings.
Insider Transactions: Since September 16, 2016, the stock had 0 insider buys, and 3 sales for $19.81 million net activity. BRANCACCIO JOHN P sold $14,504 worth of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on Monday, September 19. PAULSON & CO. INC. sold $19.49 million worth of stock or 3.47M shares.
SGYP Company Profile
Synergy Pharmaceuticals Inc. (Synergy), incorporated on February 11, 1992, is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.